Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Chonluten Dosage Protocol | PeptideDosages.com

Chonluten (20 mg Vial) Dosage Protocol Chonluten Dosage Chart Chonluten is dosed at 250 mcg–4 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Chonluten (20 mg Vial) Dosage Protocol

Chonluten Dosage Chart

Chonluten is dosed at 250 mcg–4 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 6.67 mg/mL concentration.

Typical daily range: 250–4,000 mcg once daily (gradual titration over 8–16 weeks).

Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.67 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: refrigerate at 4 °C (39.2 °F) short‑term or freeze at −20 °C (−4 °F) long‑term; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Chonluten is a short bioregulatory tripeptide (Glu‑Asp‑Gly) studied for its effects on bronchopulmonary tissue and inflammatory pathways in monocyte/macrophage cell models[1]. As a small peptide with poor oral stability, subcutaneous injection is the indicated parenteral route[2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Chonluten Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = 6.67 mg/mL)

Weeks 1–2

250 mcg (0.25 mg)

3.75 units (0.0375 mL)

Weeks 3–4

500 mcg (0.5 mg)

7.5 units (0.075 mL)

Weeks 5–6

1,000 mcg (1 mg)

15 units (0.15 mL)

Weeks 7–8

1,500 mcg (1.5 mg)

22.5 units (0.225 mL)

Weeks 9–10

2,000 mcg (2 mg)

30 units (0.30 mL)

Weeks 11–12

3,000 mcg (3 mg)

45 units (0.45 mL)

Weeks 13–14

4,000 mcg (4 mg)

60 units (0.60 mL)

Weeks 15–16

Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations during Weeks 1–4, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (Chonluten, 20 mg each):

8 weeks ≈ 3 vials (45.5 mg total)

12 weeks ≈ 6 vials (115.5 mg total)

16 weeks ≈ 12 vials (227.5 mg total)

Insulin Syringes (U‑100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (3 vials): 9 mL → 1 × 10 mL bottle

12 weeks (6 vials): 18 mL → 2 × 10 mL bottles

16 weeks (12 vials): 36 mL → 4 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Teduglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Teduglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Human SNAP-8 Research Formulations

Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone. Lipotec developer panel[6] Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide Twice daily around the eye area for 28 days 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported Manufacturer-reported, not an independent peer-reviewed trial Shin et al. (2024)[1] 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA Overnight nightly through day 14, then every third day through day 28 24 enrolled and 21 completed a split-face active-versus-placebo comparison Combination device; SNAP-8’s independent contribution cannot be isolated Avcil et al. (2020)[2] HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts 12-week study Fine lines, hydration, dermal density, thickness, and tolerability measures Multi-active product; SNAP-8 concentration was not disclosed in the abstract Draelos et al. (2016)[3] Multi-peptide serum containing SNAP-8 within a supporting skincare regimen Morning and evening for 12 weeks after a 2-week washout 29 women; investigator grading and participant questionnaires Open label, no control, multiple peptides and supporting products Moy et al. (2023)[4] Proprietary multi-peptide facial serum containing acetyl octapeptide-3 Twice daily for 12 weeks 31 women completed dermatologist grading, imaging, hydration, and questionnaires Uncontrolled, multi-ingredient, and company funded

Source: peptidedosages.com ↗

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

AOD-9604’s clinical record lives almost entirely in obesity, and understanding it is the fairest way to gauge whether any of the preclinical antilipogenic promise translated to people. The short version: it was tested seriously, in humans, at scale, and it did not deliver on its primary endpoint — and none of the human work measured lipogenesis at all. Across development, AOD-9604 was studied in roughly six human clinical trials enrolling more than 900 participants in total, a tally that derives from the sponsor’s development-program summary rather than a single publication.10 The centerpiece early study, a 12-week Phase 2 evaluation in obese adults (METAOD005) using once-daily oral dosing across several dose arms, was encouraging: the 1 mg arm reportedly lost more weight than placebo, and the results generated optimistic press.10 But the pivotal, longer, more rigorously controlled 24-week study (METAOD006) — a randomized, double-blind, placebo-controlled, multicenter trial that is the single published RCT on the compound — found that the weight-loss difference between AOD-9604 and placebo did not reach statistical significance at the primary endpoint, especially against a background of intensive diet and exercise.10 Development as an obesity drug was terminated in 2007. Two points matter for the antilipogenic question. First, every human study used weight and body-composition endpoints, plus safety and pharmacokinetic measures. None used the tools that actually quantify de novo lipogenesis in people — stable-isotope tracers (for example, deuterated water incorporation into palmitate), adipose or hepatic lipogenic-gene expression, or measured lipogenic flux. So even the human trials that exist are silent on whether AOD-9604 reduces fat synthesis; they measured the downstream outcome (weight), not the mechanism (lipogenesis), and the downstream outcome was not robustly positive. Second, the reassuring endocrine profile held up: the compound was reported not to raise IGF-1 and not to impair glucose tolerance, consistent with the “GH activity modulation” design.1 Trials ~6 studies, >900 participants total10 Pivotal design 24-week randomized, double-blind, placebo-controlled, multicenter (METAOD006); oral10 Primary endpoint Weight difference vs placebo did NOT reach statistical significance10 Lipogenesis measured? No — no DNL tracer, lipogenic-gene, or flux endpoints in any human study Endocrine profile No reported IGF-1 rise; no impaired glucose tolerance1 Outcome Obesity development halted in 200710 The honest reading is stark: the compound’s best-evidenced outcome (fat loss in obesity) was itself not robustly demonstrated in humans, and its proposed mechanism (reduced lipogenesis) was never measured in humans at all. Extrapolating from “inhibited ACC in rat fat pads” to “reduces lipogenesis in people” is a leap across species, tissues, and measurement methods, with no human data on the far side. For a measured look at how the clinical results are often characterized, see the site’s summary of what clinical trials indicate about the fat-burning potential of AOD-9604.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step Frequency: one subcutaneous injection each day. The 4 mg/day dose and the 1–4–8 mg dose-ranging arms are real Phase 2 parameters[3][4], but Phase 2 results are early-stage and proven efficacy should not be assumed.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →